These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 30673759)

  • 1. Clinical performance of Anyplex II HPV28 by human papillomavirus type and viral load in a referral population.
    Baasland I; Romundstad PR; Eide ML; Jonassen CM
    PLoS One; 2019; 14(1):e0210997. PubMed ID: 30673759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HPV detection technologies: Hybrid capture 2, PreTect HPV-Proofer and analysis of HPV DNA viral load in HPV16, HPV18 and HPV33 E6/E7 mRNA positive specimens.
    Keegan H; Mc Inerney J; Pilkington L; Grønn P; Silva I; Karlsen F; Bolger N; Logan C; Furuberg L; O'Leary J; Martin C
    J Virol Methods; 2009 Jan; 155(1):61-6. PubMed ID: 18955086
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and Analytical Evaluation of the Anyplex II HPV HR Detection Assay within the VALGENT-3 Framework.
    Oštrbenk A; Xu L; Arbyn M; Poljak M
    J Clin Microbiol; 2018 Nov; 56(11):. PubMed ID: 30209184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Performance and Diagnostic Accuracy of Human Papillomavirus Testing on Self-Collected Urine and Vaginal Samples in a Referral Population.
    Cho HW; Hong JH; Min KJ; Ouh YT; Seong SJ; Moon JH; Cho SH; Lee JK
    Cancer Res Treat; 2021 Jul; 53(3):829-836. PubMed ID: 33421987
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anyplex II HPV test in detection and follow-up after surgical treatment of CIN2+ lesions.
    Bottari F; Iacobone AD; Radice D; Preti EP; Preti M; Franchi D; Piana AF; Sandri MT; Passerini R
    J Med Virol; 2021 Nov; 93(11):6340-6346. PubMed ID: 33565607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anyplex II HPV28 detection and Anyplex II HPV HR detection assays are highly concordant with other commercial assays for detection of high-risk HPV genotypes in women with high grade cervical abnormalities.
    Cornall AM; Poljak M; Garland SM; Phillips S; Tan JH; Machalek DA; Quinn MA; Tabrizi SN
    Eur J Clin Microbiol Infect Dis; 2017 Mar; 36(3):545-551. PubMed ID: 27822653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of CIN2+ /CIN3+ risk of different HPV subtypes infection combined with abnormal cytology status].
    Luo HX; Du H; Liu ZH; Zhang LJ; Wang C; Wu RF
    Zhonghua Zhong Liu Za Zhi; 2018 Mar; 40(3):232-238. PubMed ID: 29575846
    [No Abstract]   [Full Text] [Related]  

  • 8. Predicting CIN2+ when detecting HPV mRNA and DNA by PreTect HPV-proofer and consensus PCR: A 2-year follow-up of women with ASCUS or LSIL Pap smear.
    Molden T; Nygård JF; Kraus I; Karlsen F; Nygård M; Skare GB; Skomedal H; Thoresen SO; Hagmar B
    Int J Cancer; 2005 May; 114(6):973-6. PubMed ID: 15645423
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Agreement between the AMPLICOR Human Papillomavirus Test and the Hybrid Capture 2 assay in detection of high-risk human papillomavirus and diagnosis of biopsy-confirmed high-grade cervical disease.
    Carozzi F; Bisanzi S; Sani C; Zappa M; Cecchini S; Ciatto S; Confortini M
    J Clin Microbiol; 2007 Feb; 45(2):364-9. PubMed ID: 17122008
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of the AMPLICOR human papillomavirus test and the hybrid capture 2 assay for detection of high-risk human papillomavirus in women with abnormal PAP smear.
    De Francesco MA; Gargiulo F; Schreiber C; Ciravolo G; Salinaro F; Manca N
    J Virol Methods; 2008 Jan; 147(1):10-7. PubMed ID: 17854914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of cervical intraepithelial neoplasia grade 2+ (CIN2+) using HPV DNA testing after a diagnosis of atypical squamous cell of undetermined significance (ASC-US) in Catalonia, Spain.
    Ibáñez R; Moreno-Crespi J; Sardà M; Autonell J; Fibla M; Gutiérrez C; Lloveras B; Alejo M; Català I; Alameda F; Casas M; Bosch FX; de Sanjosé S
    BMC Infect Dis; 2012 Jan; 12():25. PubMed ID: 22280073
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Triage of women with minor abnormal cervical cytology: meta-analysis of the accuracy of an assay targeting messenger ribonucleic acid of 5 high-risk human papillomavirus types.
    Verdoodt F; Szarewski A; Halfon P; Cuschieri K; Arbyn M
    Cancer Cytopathol; 2013 Dec; 121(12):675-87. PubMed ID: 23881840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Head-to-Head Comparison of DH3 HPV Test and HC2 Assay for Detection of High-Risk HPV Infection in Residual Cytology Samples from Cervical Cancer Screening Setting: Baseline and 3-Year Longitudinal Data.
    Fu Y; Li X; Li Y; Lu W; Xie X; Wang X
    Microbiol Spectr; 2022 Feb; 10(1):e0157021. PubMed ID: 35171029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the Anyplex II HPV28 assay with the Hybrid Capture 2 assay for the detection of HPV infection.
    Kwon MJ; Roh KH; Park H; Woo HY
    J Clin Virol; 2014 Apr; 59(4):246-9. PubMed ID: 24568964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical performance of the PreTect HPV-Proofer E6/E7 mRNA assay in comparison with that of the Hybrid Capture 2 test for identification of women at risk of cervical cancer.
    Ratnam S; Coutlee F; Fontaine D; Bentley J; Escott N; Ghatage P; Gadag V; Holloway G; Bartellas E; Kum N; Giede C; Lear A
    J Clin Microbiol; 2010 Aug; 48(8):2779-85. PubMed ID: 20573862
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Attributing oncogenic human papillomavirus genotypes to high-grade cervical neoplasia: which type causes the lesion?
    van der Marel J; Berkhof J; Ordi J; Torné A; Del Pino M; van Baars R; Schiffman M; Wentzensen N; Jenkins D; Quint WG
    Am J Surg Pathol; 2015 Apr; 39(4):496-504. PubMed ID: 25353286
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The PapilloCheck Assay for Detection of High-Grade Cervical Intraepithelial Neoplasia.
    Crosbie EJ; Bailey A; Sargent A; Gilham C; Peto J; Kitchener HC
    J Clin Microbiol; 2015 Nov; 53(11):3553-9. PubMed ID: 26338859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of the hybrid capture II assay with the human papillomavirus DNA chip test for the detection of high-grade cervical lesions.
    Kang WD; Kim CH; Cho MK; Kim JW; Kim YH; Choi HS; Kim SM
    Int J Gynecol Cancer; 2009 Jul; 19(5):924-8. PubMed ID: 19574786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.